Why you should buy Orphazyme A/S(ORPH) now?

$Orphazyme A/S(ORPH)$Looking towards the future we can see that Orphazyme has huge growth capabilities which can be interpreted from the financial data and the pentagon chart provided byTiger. Like I said in my last featured post, IT’S JUST THE STARTING!! Why? Because if you go through the report released by Orphazyme on last Friday June 18th around 1am in U.S time, they have mentioned in the forward looking statement that the company is planning to reshuffle its efforts into the use of arimoclomol for NPC, but why though? This is because FDA ‘DID NOT REJECT’ Arimoclomol for treatment of NPC, they rather mentioned the lack of evidence therefore what the company intends to do is indeed gather more evidences, data and proof that Arimoclomol works for NPC, and reading general biological data about the drug being used as a therapeutic treatment for NPC it looks like it indeed does work and help to cure NPC, so what do we need to look forward to? We need to look forward to the company seeking the European regulatory approval for this disease because if it succeeds which is highly likely it would be the first step towards the company’s recovery and accelerated growth pace. Not to mention that it’s listed as one of the top 10 biotech stocks in Denmark, listed in Copenhagen initially.So looking forward we will be receiving good news in the 4th quarter of 2021 regarding the European regulatory approval for Arimoclomol to treat NPC disease! I would recommend a strong buy rating as the company’s stock price is undervalued and a cheap buy before it starts to pick up comingMonday!!